Bepridil: Contribution of serum assay to treatment monitoring;Bepridil: Interet du dosage serique dans la surveillance du traitement

Presse Medicale

Volumn 29, Issue 12, 2000, Pages 645-647

  Viallon, A ^a   Laporte Simitsidis, S ^a   Pouzet, V ^a   Venet, C ^a   Tardy, B ^a   Zeni F ^a   Bertrand, J C ^a  

^a SERVICE DE NEUROLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL;

AGED; ARTICLE; BRADYCARDIA; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; QT INTERVAL; SERUM; TORSADE DES POINTES; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; RISK FACTOR;

AGED; AGED, 80 AND OVER; BEPRIDIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; RISK FACTORS; TORSADES DE POINTES;

EID: 0034176270     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Coumel P, Leclercq JF, Naditch L, Pellerin D. Evaluating of drug-induced QT interval modifications in dynamic ECG. The case of bepridil. Fundam Clin Pharmacol 1993; 7:61-8.
2. Coumel P. Safety of bepridil: review of the european data. Am J Cardial 1992; 69D:75-8.
3. Jaillon P, Gerard M, Ponsonaille J. Tolérance électrocardiographique du bépridil. La lettre du pharmacologue 1991; 5:202-6.
4. Viallon A, Page Y, Lafond P. Bépridil et torsades de pointes: Les précautions d'emploi sont-elles respectées?. Thérapie 1994; 49:1-4.
5. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Cœur 1966; 59:263-72.
6. Jervell A, Lange Nielsen F. Congenital deaf mutism, functionnal heart disease with prolongation of the QT interval, and sudden deaf. Am Heart J 1957; 54:59-68.
7. Lazzara R. Mechanisms and management of congenital acquired long QT syndroms. Arch Mal Cœur 1996; 89:51-5.
8. Guize L, Iliou MC, Bayet G et al. Les torsades de pointes. Arch Mal Cœur 1993; 86:769-76.
9. Le Heuzey JY, Davy JM, Weissenburger J et al. Intervalle QT et médicaments. Recommandations pour la prescription des médicaments chez les patients atteints du syndrome de QT long. Arch Mal Cœur 1998; 91:59-66.
10. Leclercq JF, Kural S, Valere PE. Bépridil et torsades de pointes. Arch Mal Cœur 1983; 3:241-8.
11. Hollingshead LM, Faulds D, Fitton A. Bepridil: a review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 1992; 44:835-57.